Yasuhito Fujisaka
Osaka Medical and Pharmaceutical University · 112 works · 5,098 citations · h-index 19
Top works
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors
- Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial
- Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors
- Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure
- CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer
- Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors
- Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin.
- Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset
- Phase 1 Clinical Study of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Solid Tumors
- Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days
- Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation
- Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors
- Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing
- Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial
- Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors
- P-0117 Second-Line Chemotherapy with S-1 after Cisplatin and Gemcitabine Failure in Patients with Advanced Biliary Tract Cancer
- Acute Exacerbation of Pre-existing Cancer-Related Pain: An Atypical Presentation of an Amivantamab-Induced Infusion-Related Reaction
- Small-cell Lung Cancer in a Young Adult Nonsmoking Patient with Ectopic Adrenocorticotropin (ACTH) Production